KYMERA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM BROADEN PHASE 1B CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER, IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Reuters · 2d ago

Please log in to view news